The American College of Physicians (ACP) has just issued new guidelines that strongly endorses use of sildenafil (Viagra) and similar drugs for the treatment of erectile dysfunction (ED).
While the use of the PDE5 inhibitors (sidenafil, tadalifil/Cialis, and vardenifil/Levitra) for the treatment of ED in patients who have received treatment for prostate cancer is significantly less effective than in patients who have simple ED, this endorsement of the drugs as effective and safe by one of the most influential groups of primary care physicians may help to lead to a greater willingness by insurance providers to cover the use of these drugs in patients with a clear medical need (prostate cancer patients included).
The full guideline is available on the web site of the Annals of Internal Medicine, and will be published in the November issue of the journal. A media release and video commentary can be found on the web site of the American College of Physicians.
Filed under: Living with Prostate Cancer, Management | Tagged: erectile dysfunction, guideline, PDE5 inhibitor
Search for new and
ongoing trials on the
CTAG PCa web site
